New targeted therapy reduced 80% of tumours in B-Raf study

Antibody suppliers to cancer research groups commonly list BRAF on their antibody database

. A gene which encodes the B-Raf cell-signalling protein, it plays an important role in cell division, growth and secretion. However, BRAF can also function as an oncogene, being expressed in 60% of malignant melanomas. A recent study using B-Raf antibodies revealed a new targeted therapy that shrank advanced melanoma tumours in 80% of the patient group.

A member of the raf/mil group of serine threonine protein kinases, B-Raf is expressed mainly in the brain and central nervous system. It is known to play a role in the MAP kinase/ERKs cell signalling pathway, regulating mitosis by controlling mitogenic signalling from the membrane to the nucleus. In response to NGF (nerve growth factor) triggering, B-Raf activates MAP kinase, an essential protein in mitosis.

Although this mechanism is tightly controlled, B-Raf is easily mutated. Hereditary mutations cause birth defects, while acquired mutations lead to oncogenic changes. Over 30 BRAF oncogene variants have been identified, although over 90% of human BRAF cancers are caused by just one - V600E. Mutated BRAF varies in its expression, accounting for 1 3 % of lung cancers but up to 60% of malignant melanomas. It is also widespread in colorectal and papillary thyroid cancer. With metastatic melanomas on the increase, and no significant advances in treatment since the 1990s, it is plain a drug that inhibits BRAF oncogenic activity is needed.

This may have happened. Recently, a team from the Memorial Sloan-Kettering Cancer Centre developed a new drug specifically targeting BRAF at the cellular level. In human volunteers suffering from advanced melanomas, treatment with the drug (codenamed PLX 4032), resulted in shrinkage of 80% of tumours. The trial has now progressed to Phase 3.

We at Novus Biologicals have almost 18,700 products on our antibody database devoted to cancer. Many of them, like our B-Raf antibodies, are at the forefront of medical research.

New targeted therapy reduced 80% of tumours in B-Raf study

By: Davis Morris

POST COMMENT

Collecting Information About Colleges: Choosing The Right Option BE-DO-HAVE - The Most Important Process You Will Learn - Part II of III Choosing A College: How To Choose The Right College Part2 Delhi University - The Most Reputed University Of Delhi Choosing A College: The Basic Information To Keep In Mind The Expert Best Recommendations When Learning As Well As Participating Lots Of Cooperative Board Gam Student Life In College Never Seemed So Fun For Anyone Student Life In College Focused On Its Main Charms Learn The Secrets - The Truth Revealed About Extagen Capsules Student Life In College: How To Cope With Difficulties. Student Life In College: Advantages Of College Life How To Pass An Exam: Important Prompts For Success How To Pass An Exam: Several Useful Pieces Of Advice